Dr. De Geronimo Daniele
Ophthalmologist, Researcher
Research line: Research Line of Medical and surgical retina
Research unit: RU Medical Retina
Ambulatory: Uveitis Clinic
Simple Operating Unit: Simple Operating Unit Medical Retina, low vision and visual rehabilitation
Specialization: Ophthalmology
Professional register: Provincial Register of Physicians and Surgeons of Rome (Order of the Province of Rome) No. 56668 of 10.06.2008
Practices at IRCCS Fondazione G.B. Bietti, in the facilities of Via Livenza, 3 and Via di Santo Stefano Rotondo, 6, at the Presidio Ospedaliero Britannico, Rome.
Scientific Publications: PubMed
- 2012: Specialization in Ophthalmology at the “Sapienza” University of Rome, graduating with full marks and honors (cum laude).
- 2011–2012: Uveitis and Medical Retina Fellowship at Moorfields Eye Hospital, London, UK.
- 2007: Degree in Medicine and Surgery (MD) at the “Sapienza” University of Rome, graduating with full marks and honors (cum laude).
- Since 2015: Clinical and scientific activity at the Presidio Britannico within the San Giovanni-Addolorata Hospital Company.
- Since 2013: Physician Researcher, UOS Medical Retina, IRCCS Fondazione Bietti.
- 2012: Collaborative contract with IRCCS – Fondazione Bietti with the assignment to execute the project: “Inflammatory changes of the ocular surface in patients undergoing anti-glaucoma therapy.
- 2020–Present: Permanent Staff Researcher in the Medical Retina service, IRCCS Fondazione Bietti.
- 2013–2019: Contract Researcher in the Medical Retina service, IRCCS Fondazione Bietti.
- Member of the Italian Society of Ophthalmological Sciences (SISO).
- Member of the Italian Society of Uveitis and Ocular Inflammatory Diseases (SIUMIO).
- Member of the Italian Retina Society (SIR).
- Member of the Association for Research in Vision and Ophthalmology (ARVO).
Sub-Investigator in the following Clinical Trials:
- A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV) (MINERVA). Novartis. Sub-Investigator.
- A 12-month, phase IIIb, randomized, single-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in Treat and Extend regimen compared to Monthly regimen, in patients with neovascular agerelated macular degeneration (TREND). Novartis. Sub-Investigator.
- A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista™ (Anti PDGF-B pegylated aptamer) administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal neovascular age-related macular degeneration ( Fovista-OPH1002 ). Ophthotec. Study Coordinator.
- A Phase II multicenter, randomizes, double-maskerd, sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patents with geographic atrophy secondary to o age-related macular degeneration. (CHROMA)
- A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy (Fovista-OPH1004)
- Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (SEQUOIA)
- Retinal and cognitive dysfunction in Type 2 Diabetes: unraveling the common pathways and identification of patients at risk of dementia (RECOGNISED)
- Characterization of retinal disease progression in eyes with NPDR in Diabetes Type 2 using non-trattive invasive procedures (CHART)
- Acta Ophthalmologica
- Acta Diabetologica
- European Journal Of Ophthalmology
- Ophthalmologica
- Scientific Reports
- Diabetes Therapy
- BMC Ophthalmology
- American Journal of Case Reports
- Author of 22 English-language publications in international ophthalmology journals.
- Author of 4 book chapters in Italian and English.
